Join
Live feed
·
PRReleasevia Quantisnow
Aurinia Pharmaceuticals Inc logo

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development

ByQuantisnow·Wall Street's wire, on your screen.
AUPH· Aurinia Pharmaceuticals Inc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AUPH (Aurinia Pharmaceuticals Inc) and more on Quantisnow.